Your browser doesn't support javascript.
loading
Cardio-oncology: an overview on outpatient management and future developments.
Teske, A J; Linschoten, M; Kamphuis, J A M; Naaktgeboren, W R; Leiner, T; van der Wall, E; Kuball, J; van Rhenen, A; Doevendans, P A; Cramer, M J; Asselbergs, F W.
Afiliação
  • Teske AJ; Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands. a.j.teske@gmail.com.
  • Linschoten M; Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Kamphuis JAM; Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Naaktgeboren WR; Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Leiner T; Department of Radiology, Utrecht University Medical Centre, Utrecht, The Netherlands.
  • van der Wall E; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Kuball J; Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • van Rhenen A; Department of Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Doevendans PA; Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Cramer MJ; Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Asselbergs FW; Netherlands Heart Institute, Utrecht, The Netherlands.
Neth Heart J ; 26(11): 521-532, 2018 Nov.
Article em En | MEDLINE | ID: mdl-30141030
ABSTRACT
Recent advances in the early detection and treatment of cancer have led to increasing numbers of cancer survivors worldwide. Nonetheless, despite major improvements in the outcome of these patients, long-term side effects of radio- and chemotherapy affect both patient survival and quality of life, independent of the oncological prognosis. Chemotherapy-related cardiac dysfunction is one of the most notorious short-term side effects of anticancer treatment, occurring in ~10% of patients. Progression to overt heart failure carries a strikingly poor prognosis with a 2-year mortality rate of 60%. Early detection of left ventricular damage by periodic monitoring and prompt initiation of heart failure treatment is key in improving cardiovascular prognosis. To meet the growing demand for a specialised interdisciplinary approach for the prevention and management of cardiovascular complications induced by cancer treatment, a new discipline termed cardio-oncology has evolved. However, an uniform, multidisciplinary approach is currently lacking in the Netherlands. This overview provides an introduction and comprehensive summary of this emerging discipline and offers a practical strategy for the outpatient management of this specific patient population.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Screening_studies Idioma: En Revista: Neth Heart J Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Screening_studies Idioma: En Revista: Neth Heart J Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda